Dr. Reddy's Laboratories (DRREDDY) — Financial Results

Dr. Reddy's Laboratories reported Q3 FY26 consolidated revenues of ₹8,727 crores, growing 4.4% YoY despite a 0.9% QoQ decline. EBITDA reached ₹2,049 crores (23.5% margin), up 11% YoY but down 13% QoQ, while PAT stood at ₹1,210 crores (13.9% margin), up 14% YoY but down 16% QoQ. A one-time provision for new Indian Labour Codes impacted reported profitability. Underlying financials showed stronger momentum, with double-digit base business growth offset by Lenalidomide headwinds in North America. Global Generics grew 7% YoY, while India surged 19% YoY and Emerging Markets expanded 32% YoY. Strategic advances included Semaglutide approval in India, denosumab biosimilar launch in Germany, and an Immutep immunotherapy collaboration.

📄 View Original Announcement (PDF)

📊 Stock Analysis — DRREDDY ✨ Ask AI About This

About Dr. Reddy's Laboratories Limited (DRREDDY)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,11,568.6 Cr P/E: 20.0 ROE: 16.6% ROCE: 19.7%

View full DRREDDY stock details →

📡 Get AI alerts when DRREDDY files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DRREDDY — Free

💡 Ask AI about this filing

"How does this financial results affect Dr. Reddy's Laboratories Limited's outlook?" "What did Dr. Reddy's Laboratories Limited announce on 21 January 2026?" "Is this positive or negative for DRREDDY?"

Ask AI Free →

📊 More DRREDDY filings

See all DRREDDY filings →

🔥 Also filed on 21 January 2026

SRF SRF Limited Corporate Action SRF SRF Limited Financial Results TATASTEEL Tata Steel Limited Announcement VEDL Vedanta Limited Corporate Action SUNPHARMA Sun Pharmaceutical Industries Limited Financial Results BEL Bharat Electronics Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DRREDDY files new disclosures

Track DRREDDY filings, board meetings, and corporate actions. Free email alerts at 5 PM.